--- title: "What Is MASH? Retatrutide's Liver-Disease Program Explained" description: "How retatrutide targets MASH liver disease: the glucagon-driven liver-fat effect, plus what the SYNERGY-OUTCOMES and MACELD Phase 3 trials aim to prove." url: https://retatrutide.med/blog/synergy-outcomes-maceld-mash-explained date: 2026-07-22 lastUpdated: 2026-07-22 author: "retatrutide.med Editorial" category: "analysis" tags: ["synergy-outcomes", "maceld", "mash", "masld", "retatrutide", "liver disease", "glucagon receptor", "nct07165028", "phase 3", "liver fat"] source: retatrutide.med sourceType: "blog post" license: CC-BY-NC-SA-4.0 canonical: https://retatrutide.med/blog/synergy-outcomes-maceld-mash-explained --- ## The short answer: two Phase 3 trials, one liver program Retatrutide's liver-disease program rests on two large Phase 3 trials — **SYNERGY-OUTCOMES** and **MACELD** — designed to test whether the drug can slow or prevent the damage caused by metabolic liver disease (MASLD and its inflammatory form, MASH). Both trials also test Eli Lilly's approved dual agonist tirzepatide against placebo, and both are built to measure hard liver outcomes and tissue-level change rather than the fast weight-loss numbers that made retatrutide famous. Retatrutide is investigational and is not approved for any use, including liver disease. The program grew out of one striking Phase 2 result: an approximately **82% relative reduction in liver fat** at the highest dose (Sanyal et al., _Nature Medicine_, 2024). This post explains what these trials are built to prove, why a glucagon-containing drug is unusually well suited to the liver, and why — unlike the obesity and diabetes readouts — answers here will take years, not months. ## MASLD and MASH, without the jargon **MASLD** (metabolic dysfunction-associated steatotic liver disease) is the modern name for what used to be called non-alcoholic fatty liver disease. It means too much fat stored in the liver of someone who does not drink heavily. On its own, that fat is often silent. The problem is progression. When fat accumulation is joined by inflammation and cell injury, the disease becomes **MASH** (metabolic dysfunction-associated steatohepatitis) — the form that can scar the liver (fibrosis), and over years advance to cirrhosis, liver failure, or liver cancer. MASLD is among the most common chronic liver conditions in the world, and until recently the medicine cabinet for it was nearly bare. That combination — huge population, few options — is exactly why retatrutide's liver signal drew so much attention. ## Why a glucagon drug is built for the liver Retatrutide is a **triple agonist**: a single once-weekly injection that activates the GLP-1, GIP, and glucagon receptors at the same time. The GLP-1 and GIP arms drive appetite reduction and better blood-sugar control. The glucagon arm is the one that matters most for the liver. Glucagon-receptor activation acts **directly on liver cells**, telling them to burn stored fat — a process called hepatic fatty-acid oxidation (Coskun et al., _Cell Metabolism_, 2022). That is a different lever from weight loss. Semaglutide and tirzepatide lower liver fat largely as a downstream consequence of shedding pounds and improving insulin sensitivity. Retatrutide adds a mechanism that clears hepatic fat on top of that. This is [why the glucagon receptor matters](/blog/why-glucagon-receptor-matters): it is the pharmacological reason retatrutide reduces liver fat beyond what weight loss alone can explain. ## The Phase 2 signal that justified going big In a Phase 2 substudy, retatrutide at its highest dose cut liver fat by roughly 82% on average, measured by MRI (Sanyal et al., _Nature Medicine_, 2024). A large majority of participants who started with elevated liver fat returned to normal levels — below the threshold that defines a fatty liver. We cover the full imaging data and the mechanism in depth in [liver fat reduction](/knowledge-base/liver-fat-reduction) and in [retatrutide liver fat and MASLD potential](/blog/retatrutide-liver-fat-masld-potential). Here is the catch, and the reason the Phase 3 trials exist. Liver fat is a **surrogate** — a stand-in marker. Reducing it is encouraging, but regulators, hepatologists, and patients ultimately care about two harder questions: does the drug repair the diseased tissue, and does it prevent the events that end lives? Phase 2 could not answer either. That is the job handed to SYNERGY-OUTCOMES and MACELD. ## SYNERGY-OUTCOMES: does it prevent liver events? SYNERGY-OUTCOMES is a Phase 3 **outcomes** trial in people with high-risk MASLD/MASH. Rather than counting liver fat, it counts events. Its primary endpoint is a composite of **major adverse liver outcomes (MALO)** — the serious milestones of failing liver disease, generally comprising: - progression to cirrhosis - hepatic decompensation (complications such as fluid buildup or internal bleeding) - liver transplantation - liver cancer (hepatocellular carcinoma) - death from liver-related causes This is an **event-driven** design: the trial continues until enough of these events have accumulated to give a statistically reliable answer, which is why it is measured in years. It borrows the logic of the cardiovascular outcomes trials that reshaped diabetes drug development, and applies it to the liver for the first time with this class of medicine. Critically, SYNERGY-OUTCOMES tests **retatrutide and tirzepatide, both against placebo**, inside one framework. Because tirzepatide activates GLP-1 and GIP but not glucagon, the head-to-head structure asks a clean scientific question: does adding glucagon agonism translate into fewer liver events, or is weight loss doing most of the work? You can read more on the [SYNERGY-OUTCOMES trial page](/clinical-trials/synergy-outcomes). ## MACELD: the tissue-and-fibrosis trial MACELD, which began in the fourth quarter of 2025, approaches the liver from the other direction. It enrolls patients with high-risk MASH who already have **fibrosis** — established scarring — and, like SYNERGY-OUTCOMES, studies both retatrutide and tirzepatide. Where the outcomes trial asks whether treatment prevents catastrophic events, a fibrosis-focused trial is oriented toward whether treatment can improve the diseased tissue itself: resolving steatohepatitis and slowing, halting, or reversing the scarring that drives progression. Together the two trials cover the disease from complementary angles — one measuring what happens to patients, the other measuring what happens to their livers. ## How the two liver trials compare | Trial | What it primarily measures | Population | Drugs tested | Question it answers | |---|---|---|---|---| | SYNERGY-OUTCOMES | Major adverse liver outcomes (clinical events) | High-risk MASLD/MASH | Retatrutide, tirzepatide, placebo | Does treatment prevent cirrhosis, liver failure, transplant, cancer, and liver-related death? | | MACELD | Liver tissue and fibrosis | High-risk MASH with fibrosis | Retatrutide, tirzepatide, placebo | Does treatment resolve steatohepatitis and reduce scarring? | Both are distinct from the obesity and diabetes program. They enroll a sicker, liver-specific population, and they read out on liver-specific endpoints — not the body-weight or HbA1c figures that headline the TRIUMPH and TRANSCEND trials. ## Arrived here from a trial-ID search? If you searched a raw registry number such as **NCT07165028**, you are looking at a retatrutide/tirzepatide MASLD trial listing — part of the liver program, not one of the obesity or diabetes studies. It is easy to land on a bare NCT identifier and not realize which arm of the program it belongs to. Short version: the liver trials sit apart from the weight-loss and blood-sugar trials, involve two drugs plus placebo, and are focused on the liver rather than the scale. ## Why liver answers take years The contrast in timelines is stark. The obesity trials reported at 68 to 80 weeks (TRIUMPH-4 and TRIUMPH-1), and the type 2 diabetes trial TRANSCEND-T2D-1 at 40 weeks. Fat and blood-sugar changes show up quickly. Liver events do not. Cirrhosis, decompensation, and liver cancer develop slowly, so an event-driven trial has to run long enough for a meaningful number of them to occur before it can prove anything. Histology and fibrosis change on their own unhurried clock as well. The practical upshot: expect the liver readouts to arrive well after retatrutide's obesity and diabetes data — potentially after any first regulatory filing, which industry watchers anticipate could come as early as late 2026 on the strength of the weight and glycemic results. A liver-disease label, if it comes, would be a later chapter. ## Frequently asked questions **Is retatrutide approved to treat MASH or fatty liver disease?** No. Retatrutide is investigational and not approved for any indication. The liver trials are ongoing, and no liver-disease approval exists anywhere. **Why test tirzepatide in the same liver trials?** Tirzepatide is already approved and activates GLP-1 and GIP but not glucagon. Running it alongside retatrutide lets the trials isolate whether the glucagon component adds liver benefit, or whether shared weight loss accounts for most of the effect. **When will we know if retatrutide works for liver disease?** Not soon. Because these are outcomes and tissue trials on long timelines, definitive results are years away — later than the obesity and diabetes readouts that have already reported. ## A note on how to read this Retatrutide remains an experimental medicine. Every figure above comes from clinical trials and reflects group averages, not individual results, and the two Phase 3 liver trials described here have not yet reported. Nothing in this article is a recommendation to obtain or use retatrutide, and it is not a substitute for a conversation with a qualified clinician who knows your history. Treat it as a map of where the science is heading, not as medical advice.